{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["ND 3 day Notice DRAFT Posaconaz"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":0,"defined_names":0,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"ND 3 day Notice DRAFT Posaconaz","index":0,"n_rows":2,"n_cols":9,"rows_kept":2,"cut":false,"hidden":false,"merged":[]}
["NDC11","NDC Description","Trade or Generic","Trade Name","Generic Name","Manufacturer","Date Introduced","WAC","Reason for Exceeding Threshold"]
["67457-665-20","Posaconazole 300mg/16.7mL SDV","G",null,"Posaconazole 300mg/16.7mL SDV","Mylan Institutional LLC ","2024-03-22",503.93,"Mylan utilizes a value-based methodology determined by individual product specific negotiations with customers that is a direct result of market forces including competition and supply and demand. Mylan sells its products directly to its customers, which include wholesalers, distributors, retail pharmacy chains, long-term care facilities and mail order pharmacies. Mylan also sells its generic products indirectly to several entities, including independent pharmacies, managed care organizations, hospitals, etc. These customers, called “indirect customers,” purchase our products primarily through our wholesale customers. Mylan considers various factors in determining price under its value-based methodology that includes the supply, distribution, research and development, and manufacturing costs of the product.  Mylan’s product is an FDA-approved AP-rated therapeutically equivalent generic, and Mylan priced its product competitively lower than the reference brand equivalent in order to provide a lower cost option for patients.\nOne of the most relevant factors to generic drug pricing is that the product price is provided at a lower cost than the reference brand equivalent drug. This is one of the key considerations that Mylan applies, as a generic manufacturer, in the value-based methodology Mylan uses to determine the appropriate pricing for its products. Specifically, for this product, the WAC, which serves as a reference point for pricing, at launch was 5%  below the reference brand product’s WAC.  However, there is no single formula used for Mylan’s products as a whole or for any one product.  Other factors that Mylan considers include individual negotiations with customers, competition, supply, demand.  In addition, Mylan considers the supply, distribution, research and development, and manufacturing costs."]